Lista publicaţiilor: Annals of the Rheumatic Diseases. Descărcări - 0. Vizualizări - 2012.2017 - 3
-----------------------------------------------------------------------------------------------------------------------------------
| Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (DARWIN 1) |
| Westhovens Rene, Taylor Peter Charles, Alten Rieke E.E., Pavlova Dace, Enriquez-Sosa F., Mazur Minodora, Greenwald Maria W., Van Der Aa Annegret, Vanhoutte Frederic P., Tasset Chantal, Harrison Pille |
1 Catholic University of Leuven (KU Leuven),
2 Department of Rheumatology, University Hospitals Leuven, Leuven,
3 University of Oxford,
4 Schlosspark-Klinik Innere Medizin II, Berlin,
5 LTD mandM CENTRS, Adazi,
6 CLINSTILE, S.A. de C.V, Mexico City,
7 Institute of Cardiology,
8 Desert Medical Advances, Palm Desert, CA,
9 Galapagos NV, Mechelen |
| Annals of the Rheumatic Diseases |
| Nr. / 2017 / ISSN - /ISSNe 0003-4967 |
| Disponibil online 20 February, 2018. Descarcări-0. Vizualizări-919 |
-----------------------------------------------------------------------------------------------------------------------------------
| Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: A phase II dose-ranging randomised controlled trial |
| Wallace Daniel J., Strand Vibeke, Merrill Joan T., Popa Serghei, Spindler Alberto J., Eimon Aliciaf, Noi Autori |
1 Cedars-Sinai Medical Center, Los Angeles,
2 Stanford University, Palo Alto,
3 Oklahoma Medical Research Foundation, Oklahoma City,
4 Timofei Moșneaga Republican Clinical Hospital,
5 Private Medical Center of Rheumatology, Tucuman,
6 CEMIC, Buenos Aires |
| Annals of the Rheumatic Diseases |
| Nr. / 2017 / ISSN - /ISSNe 0003-4967 |
| Disponibil online 10 June, 2022. Descarcări-0. Vizualizări-243 |
-----------------------------------------------------------------------------------------------------------------------------------
